PET Scan Glycolysis Measure Predicts Survival in EGFR-Mutant Lung Cancer on Targeted Therapy
A baseline PET/CT scan's SUVmax independently predicts progression-free survival in EGFR-mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
